Tumour reactive T cells identified through transcriptional profiling predict response to multiple myeloma immunotherapy and track treatment activity.

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...

Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...

MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.